PT - JOURNAL ARTICLE AU - Fusaroli, Michele AU - Simonsen, Arndis AU - Borrie, Stephanie A. AU - Low, Daniel M. AU - Parola, Alberto AU - Raschi, Emanuel AU - Poluzzi, Elisabetta AU - Fusaroli, Riccardo TI - Identifying medications underlying communication atypicalities in psychotic and affective disorders: A pharmacosurveillance study within the FDA Adverse Event Reporting System AID - 10.1101/2022.09.05.22279609 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.05.22279609 4099 - http://medrxiv.org/content/early/2022/09/06/2022.09.05.22279609.short 4100 - http://medrxiv.org/content/early/2022/09/06/2022.09.05.22279609.full AB - Background Disruptions in language and speech are considered promising markers of affective and psychotic disorders. However, little is known about the mechanisms and confounders underlying such communicative atypicalities. Medications might have a crucial, relatively unknown role both as potential confounders and relatedly offering an insight about the mechanisms at work. The integration of regulatory documents with pharmacovigilance techniques could provide a more comprehensive picture to account for in future investigations of communication-related biomarkers.Objectives Our aim was to identify a list of drugs potentially associated with speech and language atypicalities within psychotic and affective disorders.Methods To structure a search for potential drug-induced communicative atypicalities on the FDA Adverse Event Reporting System (FAERS, updated June 2021), we developed a query using the Medical Dictionary for Regulatory Activities (MedDRA). We performed a Bonferroni corrected disproportionality analysis (Reporting Odds Ratio) on three separate populations: psychotic, affective, and non-neuropsychiatric disorders, to account for the confounding role of different underlying conditions. Unexpected drug adverse event associations, which were not already reported in the SIDER database of labeled adverse drug reactions, were subjected to further robustness analyzes to account for expected biases.Results We identified a list of 291 expected and 91 unexpected potential confounding medications. We corroborated known/suspected associations: e.g., corticosteroids-related dysphonia and immunosuppressant-related stuttering. We also identified novel signals: e.g., domperidone-associated aphasia or VEGFR inhibitors-related dysphonia.Conclusions We provide a list of medications to account for in future studies of communication-related biomarkers in affective and psychotic disorders. The methodological tools here implemented for large scale pharmacosurveillance investigations will facilitate future investigations of communication-related biomarkers in other conditions and provide a case study in more rigorous procedures for digital phenotyping in general.Competing Interest StatementRF has been a paid consultant for F. Hoffmann - La Roche.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available anonymous human data collected by the FDA and made freely available at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present study are available online at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. The data produced in the present study are available upon reasonable request to the authors. https://osf.io/e374k/